Belize vs Cameroon: Average cost of multi drug-resistant tuberculosis treatment
Belize
3,017 constant 2022 US$
in 2024
Cameroon
2,825 constant 2022 US$
in 2024
Belize rank
15th
Cameroon rank
17th
Average cost of multi drug-resistant tuberculosis treatment over time
- Belize
- Cameroon
How they compare
Belize currently reports 3,017 constant 2022 US$ against 2,825 constant 2022 US$ in Cameroon, a difference of 192 constant 2022 US$.
That makes Belize's figure about 1.1 times Cameroon's.
Across all 7 years both countries report, Belize has been ahead every year.
Belize ranks 15th and Cameroon ranks 17th of 92 countries.
Belize has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Belize | Cameroon | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,334 constant 2022 US$ | 784 constant 2022 US$ | 2,550 constant 2022 US$ | Belize |
| 2020s | 2,028 constant 2022 US$ | 864.4 constant 2022 US$ | 1,164 constant 2022 US$ | Belize |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Belize or Cameroon?
- Belize, at 3,017 constant 2022 US$ against 2,825 constant 2022 US$ in Cameroon as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Belize and Cameroon?
- 192 constant 2022 US$, with Belize ahead.
- How many years of comparable data are there for Belize and Cameroon?
- 7 years are reported by both, from 2017 to 2024.
- How do Belize and Cameroon rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Belize ranks 15th and Cameroon ranks 17th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.